Tech manufacturer Kimball Electronics, Inc. recently shared news of a major international acquisition. The firm bought Helvoet Polymer Technologies B.V. This strategic purchase establishes a powerful global medical CDMO platform for healthcare manufacturing.
The acquired firm specializes in microfluidics, diagnostics, and advanced drug delivery. Right now, Helvoet operates major production facilities across both Europe and India to support this global medical CDMO platform. Financial Details and Strategic Impact
The financial transaction was valued at approximately 103 million dollars. Kimball funded the entire deal using cash alongside existing credit lines. Because of this, the company expects this move to boost its financial earnings by fiscal year 2027.
Furthermore, building this unified global medical CDMO platform significantly expands the manufacturer’s operational footprint outside the United States. It opens up direct access to the rapidly growing Indian healthcare market. Additionally, the deal adds a prestigious roster of blue-chip medical clients to the mix.
Kimball already operates a modern manufacturing facility located in Indianapolis. This domestic site perfectly positions the expanding global medical CDMO platform to capture immediate American demand. Existing Helvoet customers can now easily transition their production needs to the United States.
To share more details, the executive management team will host an official conference call. This live webcast will occur on Wednesday, July 1st, at 9:00 AM ET.
“Helvoet is exactly the type of acquisition we’ve been building toward, a highly specialized medical CDMO with comprehensive capabilities in microfluidics, diagnostics, and drug delivery, serving blue-chip customers in the fastest-growing segments of healthcare. The acquisition is central to our strategy of establishing Kimball as a true global medical CMO platform with a strengthened presence in Europe, access to the India market, and a clear path for accelerating growth in the U.S. by leveraging our new manufacturing facility in Indianapolis.” Richard D. Phillips, Chief Executive Officer of Kimball Electronics
Mr. Phillips continued, “Today’s announcement is another meaningful step in our journey to expand our CMO capabilities and strategically position the Company with an increased presence and penetration in the medical industry. Over the past three years, we have made deliberate decisions that involved divesting non-core assets, streamlining our network, and strengthening the balance sheet. We are now leveraging that strength with the acquisition of a high-quality business at an attractive valuation. Helvoet has a talented team with strong leadership, and we’re excited to partner together and unlock synergies of the combined business. We believe this will create meaningful long-term value for our shareholders.”
Historical Background and Operations
Founded in 1939, Helvoet previously operated as a subsidiary of Hydratec Industries N.V. The specialized manufacturer maintains busy production hubs in Tilburg, Netherlands, and Pune, India.
During calendar year 2025, the firm generated roughly 56 million dollars in total revenue. Most of this income came directly from healthcare clients. The remaining revenue streams supported ongoing investments in their core medical business.
Fortunately, the current executive team will continue to run daily operations. This leadership group includes the reigning chief executive officer.
Eveline Hogenkamp, Chief Executive Officer of Helvoet, added: “Helvoet has spent decades building something genuinely differentiated design and engineering savvy, robust materials expertise, highly automated precision manufacturing, and long-term relationships with some of the world’s leading medical companies. Finding the right partner to take this business to the next level was critical, and in Kimball we found just that. Their Indianapolis facility, customer relationships, and operational capabilities are precisely what we need to scale our U.S. presence and win larger, more complex programs. The strategic fit is as strong as any I’ve seen — complementary capabilities, shared values around engineering excellence and quality, and a clear vision for where this business can go. I couldn’t be more excited about what we’re going to build together.”
To finalize the deal, major financial advisory firms guided both corporate parties. MP Corporate Finance advised Helvoet throughout the process. Meanwhile, Roth Capital Partners acted as the exclusive financial advisor for Kimball Electronics.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
